Dr. Krop on Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

Ian Krop, MD, PhD, associate director, Cancer Center, director, Clinical Trials Office, chief clinical research officer, Yale Cancer Center, discusses findings from the phase 3 DESTINY-Breast02 trial (NCT03523585) in patients with HER2-positive metastatic breast cancer.

DESTINY-Breast02 investigated fam-trastuzumab deruxtecan-nxki (Enhertu) vs investigator’s choice of either capecitabine (Xeloda) plus trastuzumab (Herceptin) or capecitabine plus lapatinib in patients with HER2-positive, unresectable and/or metastatic breast cancer who have previously been treated with ado-trastuzumab emtansine (Kadcyla).

In this trial, trastuzumab deruxtecan elicited superior progression-free survival (PFS), with a hazard ratio of 0.36, Krop says. The median PFS was 17.8 months with trastuzumab deruxtecan vs 6.9 months with physician’s choice of treatment, Krop explains. This trial also evaluated overall survival (OS), finding a 12.7-month OS benefit in the trastuzumab deruxtecan arm vs the control arm, Krop concludes.